TP53 and acute myeloid leukemia: TP53 mutations in NK cells—often shared with malignant myeloid clones in AML or MDS—lead to increased DNA methylation, reduced expression of perforin, TNF-α, and killer immunoglobulin-like receptors (KIR), and impaired cytolytic activity.